Dana-Farber’s Breast Oncology Center shared a post on X:
“Dr. Antonio Giordano’s novel work on a next-generation CDK4/6 inhibitor is offering new hope to patients like Ellie Destito, who had exhausted standard treatments.
What began as an unnamed drug in a phase 1 trial is now being evaluated in a phase 3 trial bringing new optimism to patients and researchers alike in the fight against.”
Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared this post, adding:
“I love this story, you are a rockstar!
Thank you Dana-Farber’s CCTI to make phase 1 trials possible and give new hopes to patients with metastatic cancer!”
More posts featuring Breast Cancer.
